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Summary
Many tumors display a high rate of glucose utilization, as evidenced by 18-F-2-deoxyglucose PET imaging. One potential
advantage of catabolizing glucose through glycolysis at a rate that exceeds bioenergetic need is that the growing cell
can redirect the excess glycolytic end product pyruvate toward lipid synthesis. Such de novo lipid synthesis is necessary
for membrane production and lipid-based posttranslational modification of proteins. A key enzyme linking glucose metab-
olism to lipid synthesis is ATP citrate lyase (ACL), which catalyzes the conversion of citrate to cytosolic acetyl-CoA. ACL
inhibition by RNAi or the chemical inhibitor SB-204990 limits in vitro proliferation and survival of tumor cells displaying
aerobic glycolysis. The same treatments also reduce in vivo tumor growth and induce differentiation.S I G N I F I C A N C E
A common feature of human cancer is the conversion to a glucose-dependent form of metabolism. When a tumor cell’s glucose
metabolism exceeds its bioenergetic needs, the excess metabolites can be secreted as lactate or diverted toward the intracellular
synthesis of lipids. Lipid synthesis is required by a growing cell to synthesize membranes and lipid-modified signaling molecules. As
the regulator of the key step that can convert high glycolytic flux into increased lipid synthesis, ATP citrate lyase (ACL) is identified
as a potential molecular target for cancer therapy. This report validates ACL as a therapeutic target and provides the rationale for
the development of ACL inhibitors as antineoplastic agents against human tumors that have undergone a glycolytic conversion.Introduction
Many human cancers display a high rate of aerobic glycolysis
(Warburg, 1956), a phenomenon that is exploited in 18-F-2-
deoxyglucose positron emission tomography (FDG-PET) im-
aging for the detection of primary and metastatic tumors
(Gambhir, 2002). Upregulation of glycolytic metabolism occurs
downstream of multiple oncogenic pathways (Dang and Se-
menza, 1999; Elstrom et al., 2004) and has been shown to cor-
relate with increased tumor aggressiveness and poor patient
prognosis in several tumor types (Detterbeck et al., 2004).
These observations suggest that the glycolytic phenotype
plays a role in tumor progression by contributing to tumor
growth or survival.
High levels of glycolysis not only provide ATP for the tumor
cells’ high bioenergetic demands but may also provide precur-
sors and reducing equivalents for the synthesis of macromole-
cules, such as nucleotides, proteins, and lipids. In most tis-
sues, fatty acid synthesis occurs at low rates since lipids are
acquired via the circulation to support the needs of vegetative
nonproliferating cells. In contrast, de novo fatty acid synthesis
occurs at very high rates in tumor tissues (Kuhajda, 2000), as
first demonstrated more than half a century ago (Medes et al.,CANCER CELL : OCTOBER 2005 · VOL. 8 · COPYRIGHT © 2005 ELSEVIER1953). 14C glucose studies have shown that in tumor cells al-
most all fatty acids are derived from de novo synthesis despite
an abundant supply of extracellular lipids (Ookhtens et al.,
1984; Sabine et al., 1967). The high rate of de novo fatty acid
synthesis in rapidly proliferating cells fuels membrane biogene-
sis (Jackowski et al., 2000; Zambell et al., 2003). It is thus pos-
sible that an increase in the uptake and metabolism of glucose
contributes to enhanced tumor cell proliferation by promoting
de novo fatty acid synthesis.
The pathway for glucose-dependent de novo lipogenesis is
illustrated in Figure 1. In cells that have undergone a glycolytic
conversion, i.e., have shifted from an oxidative to a glycolytic
mode of metabolism under aerobic conditions, much of the
bioenergetic supply is provided through glycolytic ATP produc-
tion (Nakashima et al., 1984), and glycolytically derived pyr-
uvate enters a truncated TCA cycle (Baggetto, 1992; Crabtree,
1929) where citrate is preferentially exported to the cytosol via
the tricarboxylate transporter (Kaplan et al., 1993). Once in the
cytosol, citrate is cleaved by ATP citrate lyase (ACL) to produce
cytosolic acetyl-CoA and regenerate oxaloacetate (Figure 1)
(Srere, 1959). Acetyl-CoA is the requisite building block for the
endogenous synthesis of fatty acids, cholesterol, and isopren-
oids as well as acetylation reactions that modify proteins. ToINC. DOI 10.1016/j.ccr.2005.09.008 311
A R T I C L EFigure 1. ATP citrate lyase regulates the flow of
glucose carbons to cytosolic acetyl-CoA during
glucose catabolism
Upon stimulation of aerobic glycolysis, in-
creased glucose uptake and increased flux of
glucose carbons into the mitochondria as pyr-
uvate leads to an increase in the mitochondrial
concentration of citrate. Mitochondrial citrate is
transported down a concentration gradient to
the cytosol. ATP citrate lyase (ACL) cleavage of
cytosolic citrate generates acetyl-CoA and ox-
aloacetate. Acetyl-CoA is the precursor for the
synthesis of fatty acids, cholesterol, and isopren-
oids, while oxaloacetate is reduced to malate,
using NADH as an electron donor. Malate re-
turns to the mitochondrial matrix, where it is oxi-
dized to regenerate oxaloacetate. The resulting
NADH donates its electrons to the electron
transport chain to maintain the inner mem-
brane potential and oxidative phosphorylation.
Under conditions of low cellular glucose uptake,
an alternative pathway for the generation of
cytosolic acetyl-CoA is through the activation
of acetate by acetyl-CoA synthetase. ACL, ATP
citrate lyase; ACAS2, acetyl-CoA synthetase;
FAS, fatty acid synthesis; OAA, oxaloacetate;
Pyr, pyruvate; FTI, farnesyl transferase inhibitors;
ECM, extracellular matrix. (See text for details.)complete this substrate cycle, ACL-generated oxaloacetate is
reduced to malate, which can return to the mitochondria, re-
cycling carbon and shuttling reducing equivalents into the
mitochondria (Figure 1). The conversion of cytosolic oxaloace-
tate to malate is driven by the high cytosolic NADH/NAD+ ratio
present in glycolytic cells (Bauer et al., 2004). Malate can enter
the mitochondrial matrix and be converted there to oxaloace-
tate to complete the substrate cycle. The coupled conversion
of NAD+ to NADH provides a continuing mechanism to pre-
serve the mitochondrial membrane potential (MMP) and sus-
tain a high mitochondrial NADH/NAD+ ratio that maintains the
TCA cycle in a repressed state. Thus, ACL enzymatic activity
is poised to affect both glucose-dependent lipogenesis and
cellular bioenergetics.
ACL is a homotetrameric enzyme with widespread tissue
expression, which exhibits coordinate transcriptional regulation
with other enzymes in the lipogenic pathway. ACL levels in-
crease in response to signals that communicate nutritional
status, activate cellular glucose uptake and metabolism, and
stimulate anabolic growth (Towle et al., 1997). Insulin transcrip-
tionally induces and activates ACL through the PI3K/Akt path-
way in insulin-responsive tissues and tissue-specific growth
factors that activate the PI3K/Akt pathway appear to play a
similar role in other tissues (Towle et al., 1997). Insulin and
growth factor stimulation also lead to ACL phosphorylation by
Akt (Berwick et al., 2002; Buzzai et al., 2005). Furthermore, high
levels of glucose increase ACL levels synergistically with PI3K/
Akt activation (Katz and Giffhorn, 1983). It thus becomes evi-
dent that signaling pathways that contribute to a glycolytic
phenotype and play an important role in tumorigenesis can
also lead to increased ACL levels and/or activity. These path-
ways may partly account for the fact that ACL activity was
found to be significantly elevated in breast (Szutowicz et al., 1979)312and bladder (Turyn et al., 2003) carcinomas versus normal breast
and bladder tissue: 160-fold and 7-fold, respectively.
Based on ACL’s potential role in the integration of glucose
and lipid metabolism, we have assessed its potential as a ther-
apeutic target for cancer. For this purpose, we used both ge-
netic and pharmacological approaches to demonstrate that
ACL inhibition results in the suppression of proliferation and
the promotion of differentiation in glucose-dependent tumors.
These data suggest that tumors that have undergone a meta-
bolic conversion to aerobic glycolysis utilize the glucose-
dependent production of cytosolic acetyl-CoA to fuel lipid syn-
thesis. Thus, conversion to aerobic glycolysis appears to be
capable of promoting tumor growth by both stimulating lipid
synthesis and suppressing tumor cell differentiation. These
properties may contribute to selection for conversion to aerobic
glycolysis during tumor progression in vivo (the Warburg effect).
ACL inhibitors appear to have the potential to suppress the
growth of such advanced malignancies, a group that has other-
wise proven highly resistant to existing therapeutic strategies.
Results
Knockdown of endogenous ACL levels by siRNA
disturbs mitochondrial homeostasis and impairs
the proliferation and viability of tumor cells
To assess the effects of ACL inhibition on tumor cells, RNA
interference (RNAi) was used to reduce ACL levels in the hu-
man lung adenocarcinoma cell line A549. Transient transfection
of A549 cells with the ACL siRNA oligonucleotide (siACL) led
to a progressive decline in ACL protein levels compared to a
luciferase siRNA (siLUC) control. The decline in ACL protein
was modest at 24 hr post-siRNA treatment but became grad-
ually more pronounced by 48 and 72 hr posttransfection (Fig-CANCER CELL : OCTOBER 2005
A R T I C L EFigure 2. Effects of ACL knockdown by transient RNAi on lipid synthesis and
cell cycle progression in a human lung adenocarcinoma line
A: siRNA oligonucleotides targeting luciferase (“L”) or ACL (“A,” corre-
sponding to the ACL4 siRNA sequence) were transiently transfected into
A549 cells, and protein extracts were analyzed for ACL expression at the
indicated times posttransfection.
B: Levels of total cellular acetyl-CoA were compared in siLUC- versus siACL-
treated cells 7 days posttransfection as described in the Experimental Pro-
cedures and were normalized to protein concentration. Data shown are
the mean ± SEM of triplicate samples from a representative experiment.
C: Glucose-dependent (left panel) versus acetate-dependent (right
panel) lipid synthesis was compared in siLUC- versus siACL-treated cells 48
hr posttransfection. Counts for each sample were normalized to protein
concentration. Data shown are the mean ± SEM of triplicate samples from
a representative experiment.
D: siLUC (left panel) or siACL (right panel)-treated cells were pulse labeled
with 10 M BrdU 72 hr posttransfection and analyzed for BrdU incorporation
and DNA content (PI). The percentage of cells in the G1, S, and G2/M
phases is indicated for representatives of triplicate samples.ure 2A). To document the effects of ACL downregulation on
acetyl-CoA synthesis, acetyl-CoA levels in siLUC- and siACL-
treated cells were compared. Persistent repression of ACL syn-
thesis resulted in a 50% reduction in total acetyl-CoA levels in
the siACL-treated cells compared to controls (Figure 2B). As
early as 48 hr posttransfection, a significant decline in D-[6-14C]
glucose-dependent lipid synthesis was observed in the siACL-
treated cells (Figure 2C). Lipid synthesis through [1-14C]ace-
tate, which is converted to acetyl-CoA by acetyl-CoA synthetase
(ACAS2) and not ACL (Figure 1) was unaffected (Figure 2C). ByCANCER CELL : OCTOBER 200572 hr, cell accumulation in the siACL-treated population was con-
siderably slower than that of siLUC-treated cells. siACL-treated
cells exhibited an increase in the percentage of cells in the G1
phase accompanied by a decrease in S phase cells, in compari-
son to control cells (Figure 2D). This resulted in a 30% decline in
the cell number of ACL siRNA-treated cells compared to controls
but no difference in cell viability (data not shown).
To observe the effects of prolonged ACL inhibition, cells
were treated as described in Figure 2, with siLUC or two inde-
pendent ACL siRNAs (siACL1 and siACL4) for 72 hr, and then
replated at equal numbers and subjected to a second round of
siRNA transfection. During this second transfection period,
ACL protein remained at near undetectable levels (Figure 3A).
Mitochondrial effects were consistently observed during these
experiments. A time-dependent increase in MMP in ACL knock-
down cells first became apparent 72 hr posttransfection (round
1) and was maintained for the duration of the second siRNA
transfection round (Figure 3B). Cell proliferation was severely
impaired, since the cell number of ACL knockdown cells re-
mained stable, while control cells continued to proliferate (Fig-
ure 3C). Cell viability remained high, and a decrease in the via-
bility of ACL knockdown cells was observed only at late time
points (Figure 3D).
Stable knockdown of endogenous ACL levels by shRNA
suppresses tumor growth in vivo and induces glandular
differentiation in A549 lung adenocarcinoma cells
In order to study the effects of stable ACL gene knockdown on
the in vivo tumorigenicity of A549 cells, we generated expres-
sion constructs containing ACL short hairpin RNAs (shRNAs)
and established stable clones of A549 with shRNA-mediated
suppression of ACL. Two independent constructs, pKD-ACL4
(HP 4) and pKD-ACL1 (HP 1), were used to generate stable cell
lines with efficient ACL knockdown (Figure 4A). Two clones (HP
4-7 and HP 4-8) stably transfected with pKD-ACL4 and dis-
playing significantly reduced ACL levels (Figure 4A) were ana-
lyzed in detail. In concordance with the observed reduction in
ACL protein levels (Figure 4A), ACL activity in these clones de-
creased at least 10-fold (Figure 4B).
To determine their tumorigenicity in vivo, we injected vector
control (V6) and ACL knockdown clones (HP 4-7 and HP 4-8)
subcutaneously into nude mice and examined tumor formation
and progression. Injections were done in such a manner that
each mouse received a vector control inoculation in one flank
and an ACL shRNA clone in the other, so that tumor compari-
sons would be controlled for each individual mouse. The
growth of tumors was monitored weekly, and tumors were ex-
cised and weighed 60 days postinjection. The results demon-
strate that ACL knockdown cells form significantly smaller tu-
mors in vivo (Figure 4C). Western blotting of protein lysates
from the excised tumors confirmed maintenance of the ACL
knockdown phenotype by the tumor cells (data not shown).
The stable pool generated using the independent ACL shRNA
construct pKD-ACL1 (HP 1) was also compared to a vector-
transfected pool, as an independent test. The HP 1 cells grew
more slowly in vivo than the control-transfected cells inocu-
lated in the contralateral flank of the same mouse (Figure 4C).
To further investigate the underlying mechanism of tumor
suppression, we examined tumors resected from nude mice by
H&E staining (Figure 4D). Tumors from A549 vector control
cells were poorly differentiated and exhibited a disorganized313
A R T I C L EFigure 3. Effects of two independent siRNA hair-
pins targeting ACL on mitochondrial membrane
potential, cell proliferation, and viability of A549
lung cancer cells
A: Efficient knockdown of ACL protein levels by
two independent siRNA oligonucleotides in cells
transiently transfected with either luciferase (si-
LUC) or ACL (siACL1, siACL4 corresponding to
ACL1, ACL4 siRNA sequences) oligonucleotides.
Depicted are curves of mitochondrial mem-
brane potential (MMP) (B), cell proliferation (C),
and viability (D) of cells transfected with the in-
dicated siRNA oligonucleotides for two consec-
utive rounds of transfection. For B, MMP was de-
termined by TMRE staining and flow cytometry
as described in the Experimental Procedures.
The data presented in B–D correspond to the
mean ± standard deviation (SD) from a repre-
sentative experiment.cellular architecture (Figure 4D, left panel). In contrast, tumors
from clones HP 4-7 and HP 4-8 (Figure 4D, middle panel and
data not shown) as well as from the HP 1 pool (Figure 4D, right
panel) displayed a more differentiated morphology marked by
the presence of glandular structures bearing central lumens.
Since mucin production is characteristic of differentiated respi-
ratory epithelium, we examined mucin expression in these tu-
mors by staining with mucicarmine. The tumor nodules reco-
vered from the ACL knockdown cells showed intracytoplasmic
and intraluminal mucin staining (Figure 4E, middle and right
panels). In contrast, the tumors recovered from the vector
control cells, which lacked glandular structures, showed only
background staining, consistent with their poorly differentiated
phenotype (Figure 4E, left panel). Comparison of vector control
versus ACL knockdown tumors with an active caspase-3 anti-
body found no evidence for the increased presence of apo-
ptotic cells in sections from the latter group (data not shown).
Thus, the suppression of tumor growth of A549 cells in vivo
upon knockdown of ACL levels is correlated with an increased
propensity toward epithelial cell differentiation.
Stable knockdown of endogenous ACL levels by shRNA
induces differentiation in the K562 chronic myelogenous
leukemia cell line in vitro
The increased degree of differentiation observed in the A549
ACL knockdown tumors in vivo was unexpected. To determine
whether the effect was observed in other tumor cell types, we
utilized a well-characterized model of in vitro tumor cell differ-
entiation, the human chronic myelogenous leukemia cell line
K562, which is dependent on the BCR-ABL fusion protein
(Druker et al., 1996). Drugs that inhibit BCR-ABL signaling such
as Gleevec (imatinib mesylate) and Hsp90 inhibitors such as
radicicol have been promoted as therapeutic agents, based on314their ability to induce erythroid differentiation in this tumor model
(Druker et al., 1996; Shiotsu et al., 2000). We used an RNAi
approach to stably knock down endogenous ACL levels in
K562 cells and evaluate downstream effects on cellular differ-
entiation. We generated clones with efficient ACL knockdown
by stable transfection of K562 with the pKD-ACL4 shRNA con-
struct (representative clones HP 4-1 and HP 4-2 are shown in
Figure 5A). To assess their degree of erythroid differentiation,
we analyzed the cells for expression of glycophorin A (CD235a),
a surface glycoprotein expressed selectively on erythroid pre-
cursors and mature erythrocytes and shown to be induced in
K562 cells undergoing erythroid differentiation in response to
Gleevec (Kohmura et al., 2004) and radicicol (Shiotsu et al.,
2000). Compared to vector control transfected cells, ACL knock-
down cells showed an increase in the surface expression of
this erythroid cell marker (Figure 5B, left panel), comparable to
the induction obtained upon treatment of control cells with the
Hsp90 inhibitor radicicol (Figure 5B, right panel). Furthermore,
quantitation of hemoglobin-positive cells revealed that approxi-
mately 36.7% and 29.3% of cells within the HP 4-1 and HP
4-2 ACL knockdown population, respectively, expressed he-
moglobin, compared to 5% of vector control K562 cells (Fig-
ure 5C).
Inhibition of ACL activity by the pharmacologic
inhibitor SB-204990
As a complementary approach to RNAi, the effects of the ACL
chemical inhibitor SB-204990 (Pearce et al., 1998) on cell
growth and proliferation were analyzed. In order to evaluate the
effects of ACL inhibition by SB-204990 under conditions where
both glycolysis and cell proliferation can be regulated, we ex-
amined IL-3-dependent cell lines. IL-3 has been shown to di-
rectly stimulate glycolysis and cell proliferation in these cellCANCER CELL : OCTOBER 2005
A R T I C L EFigure 4. Stable knockdown of ACL levels in
A549 cells results in the generation of smaller tu-
mors in vivo displaying features of glandular dif-
ferentiation
A: Western blot analysis of cellular extracts dem-
onstrates efficient knockdown of ACL levels in
A549 cells stably transfected with ACL shRNA
constructs. The independent clones V6 and V12
were generated by stable transfection of con-
trol pKD vector, while clones HP 4-7 and HP
4-8 were generated using the pKD-ACL4 shRNA
plasmid. At right, extracts from pools of cells sta-
bly transfected with either empty pKD vector
(Vector) or with a different ACL shRNA plasmid
[pKD-ACL1(HP 1)] were compared for levels
of ACL.
B: ACL activity was measured in protein extracts
of either control (V6, V12) or the ACL shRNA sta-
ble clones (HP 4-7, HP 4-8) shown above (A).
Plotted is the mean ± SD of triplicate samples.
C: Charts depicting the weight of subcutaneous
tumors formed in nude mice 60 days after injec-
tion of either the control (V6, Vector) or the ACL
knockdown A549 stable transfectants (HP 4-7
[n = 7], HP 4-8 [n = 5], HP 1 [n = 10]) described
above (A).
D and E: Glandular differentiation is detected
by H&E staining (D), and mucin production is
detected by mucicarmine staining (E) in tumors
originating from the ACL knockdown stable
transfectants (HP 4-7, HP 1). Original magnifica-
tion is 200×.lines (Lum et al., 2005; Plas et al., 2001). A 2 hr preincubation
of cells growing in IL-3 with SB-204990 caused a dose-depen-
dent decrease in D-[6-14C]glucose-dependent lipid synthesis
(Figure 6A). Synthesis of phospholipids accounted for the bulk
of de novo lipogenesis and was thus severely impaired by ACL
inhibition (data not shown). In agreement with the RNAi results,
ACL inhibition by SB-204990 induced a dose- and time-depen-
dent increase in the MMP of cells proliferating in the presence
of IL-3 (Figure 6B and data not shown). These effects were
observed in two individual IL-3-dependent cell lines. Further-
more, when IL-3-dependent cells were treated for 24 hr with
increasing doses of SB-204990, their proliferation was inhib-
ited, and the cells displayed a dose-dependent G1 cell cycle
arrest (Figure 6C). To assay the effects of ACL inhibition on cell
growth and cell cycle entry of G1-arrested cells, we initially
withdrew growth factor from the IL-3-dependent Bax−/−Bak−/−
cells for 5 days and confirmed their G1 arrest (data not shown)
and their decrease in cell size (Figure 6D, upper panel) con-CANCER CELL : OCTOBER 2005comitantly with the downregulation of their glycolytic metabo-
lism upon growth factor withdrawal (Lum et al., 2005). Upon
readdition of IL-3, the cells are expected to progressively in-
crease in cell size and eventually reenter the cell cycle (Lum et
al., 2005). Indeed, vehicle-treated cells were able to increase
their cell size and enter the cell cycle 72 hr post-IL-3 addition
(Figure 6D and data not shown). In contrast, treatment with
increasing doses of SB-204990 resulted in a dose-dependent in-
hibition of both cell growth and cell cycle entry (Figure 6D and
data not shown). In cells treated with the 15 M SB-204990 dose,
cell cycle entry was delayed by 2 additional days, while the higher
doses inhibited cell cycle entry almost completely.
In vitro antitumor activity of the chemical ACL
inhibitor SB-204990
To test the promise of the ACL inhibitor SB-204990 as a poten-
tial cancer therapeutic, three human tumor cell lines from the
NIH 60 panel were analyzed for their in vitro sensitivity to ACL315
A R T I C L EFigure 5. Stable knockdown of ACL levels in the K562 chronic myelogenous
leukemia cell line induces erythroid differentiation
A: Western blot analysis demonstrates efficient knockdown of ACL levels in
K562 cells stably transfected with ACL shRNA constructs. The V1 clone was
generated by stable transfection of control pKD vector, while clones HP
4-1 and HP 4-2 were generated using the pKD-ACL4 shRNA plasmid.
B: Expression levels of the erythroid marker glycophorin A on the surface of
control (V1) and ACL knockdown cells (HP 4-1 and HP 4-2) were compared
using a mouse FITC-conjugated anti-human glycophorin A antibody. As
a negative control (Neg ctrl), cells were incubated with FITC-conjugated
control IgG. On the right panel, control K562 cells (V1) were left untreated
or were treated with 1.5 M radicicol for 24 hr prior to analysis, as a positive
control for glycophorin A induction.
C: The percentage of hemoglobin-expressing cells in control (V1) and ACL
knockdown (HP 4-1 and HP 4-2) cell populations was determined by benzi-
dine staining. Plotted is the mean ± SD of triplicate samples from a repre-
sentative experiment.inhibition by SB-204990 and for their ability to form tumors in
nude mice. In addition to the A549 cell line that we had pre-
viously characterized with RNAi, the cell lines PC3 and SKOV3
were examined. In vitro, all three cell lines displayed a dose-
and time-dependent sensitivity to ACL inhibition by SB-204990
(Figure 7A). Measurement of acetyl-CoA following a brief treat-
ment with SB-204990 confirmed that there was a significant
and reproducible reduction in total acetyl-CoA levels in treated
cells compared to controls (17% reduction; p < 0.001; n = 12).
Interestingly, among the cell lines tested, SKOV3 cells were
significantly more resistant to the ACL inhibitor, with a 2-fold
higher IC50 value (Figure 7A). The differences in sensitivity
correlated with the rates of glucose utilization (Figure 7B) and
lactate production (Figure 7C) of the cell lines. SKOV3 cells
utilize virtually all the glucose they take up, secreting little lac-316tate into the medium. In contrast, A549 and PC3 cells utilize
much higher levels of glucose and secrete a large percentage
of the glucose carbons they take up into the medium as lactate
(Figures 7B and 7C). Consistently with their higher rate of gly-
colysis (data not shown), A549 and PC3 cells exhibited a 3- to
4-fold higher rate of D-[6-14C]glucose-dependent lipid synthe-
sis than SKOV3 cells (Figure 7D).
To further define the requirements for sensitivity to ACL inhi-
bition in glucose-dependent cells, we utilized a genetic model
of paired wild-type and cytochrome c null mouse embryonic
cell lines (Mansfield et al., 2005). The latter cells lack a func-
tional mitochondrial respiratory chain and are thus solely de-
pendent on anaerobic glycolysis for their ATP demands. Since
these cells cannot oxidize NADH through electron transport,
glycolytic pyruvate is preferentially secreted as lactate rather
than entering the mitochondrial TCA cycle. As a result, cyto-
chrome c null cells exhibited a 4-fold lower rate of D-[6-14C]
glucose-dependent lipid synthesis and a 2.5-fold increase in
acetate-to-lipid synthesis in comparison to wild-type cells (see
Figure S1A in the Supplemental Data available with this article
online). In addition, cytochrome c null cells were significantly
more resistant to SB-204990 than their wild-type counterparts
(Figure S1B). Thus, cells lacking in the ability to engage in aero-
bic glycolysis display reduced dependence on glucose-depen-
dent lipid synthesis and ACL activity.
In vivo antitumor activity of the chemical ACL
inhibitor SB-204990
To evaluate the antineoplastic activity of SB-204990 in vivo, we
utilized xenograft tumor models in nude mice using the three
cell lines from the NIH 60 panel described above. In compar-
ison to treatment with vehicle alone, SB-204990 showed sig-
nificant antineoplastic activity against both A549 and PC3
xenografts (Figure 7E). The effects of the ACL inhibitor in vivo
appeared to be cytostatic, as both A549 and PC3 xenografts
showed significant inhibition of tumor growth but no tumor re-
gression during the treatment period. Histologic comparison
of control- and SB-204990-treated A549 xenografts revealed a
more differentiated morphology in the latter group, which was
marked by the presence of glandular structures showing intra-
cytoplasmic and intraluminal mucin expression (Figure S2) and
similar to what we previously observed upon genetic knock-
down of ACL levels in A549 cells (Figure 4E). Analysis of tumor
sections for caspase activation to detect apoptotic cells con-
firmed that the effects of the treatment were predominantly
cytostatic, as no significant difference in active caspase-3-pos-
itive cells was observed between the ACL-treated and control-
treated tumors (Figure S2). No effect of SB-204990 treatment
was observed on SKOV3 xenografts in three independent ex-
periments. Mice treated with the SB-204990 drug sustained a
significant decrease in their body weight compared to controls.
While vehicle-treated mice displayed a 2.1% ± 0.6% weight
gain upon completion of treatment, their SB-204990-treated
counterparts sustained a 6.8% ± 1.2% weight loss. Similar de-
clines in body weight have been reported previously for ACL
inhibitors (Pearce et al., 1998; Shara et al., 2003).
To extend the analysis of the in vivo efficacy of SB-204990,
two independent primary pancreatic ductal cell lines were ex-
amined (Figure 8). These cell lines were derived from mice ex-
pressing endogenous oncogenic K-rasG12D (Hingorani et al.,
2003) in a p53 wild-type (Figure 8A) or p53 point mutant back-CANCER CELL : OCTOBER 2005
A R T I C L EFigure 6. Effects of the chemical ACL inhibitor
SB-204990 on lipid synthesis, mitochondrial mem-
brane potential, cell cycle progression, and
cell growth
A: Bcl-xL FL5.12 cells (Plas et al., 2001) were incu-
bated for 2 hr with the indicated doses of SB-
204990 or vehicle followed by an additional 2 hr
incubation with D-[6-14C]glucose as the radio-
active precursor for lipid synthesis. Plotted is the
mean ± SEM of triplicate samples from a repre-
sentative experiment.
B: Bcl-xL FL5.12 cells were incubated for 2 hr with
the indicated doses of SB-204990 (inh) or vehicle
followed by staining with TMRE in the presence
or absence of the uncoupler FCCP for the flow
cytometric determination of mitochondrial mem-
brane potential.
C: IL-3-dependent hematopoietic Bax−/−Bak−/−
cells (Lum et al., 2005) were pulse labeled with
10 M BrdU after a prior 24 hr incubation with
the indicated doses of SB-204990 (inh) or vehicle
and analyzed for BrdU incorporation and DNA
content (PI) to determine cell cycle progression.
D: The Bax−/−Bak−/− IL-3-dependent cells were
withdrawn from IL-3 for 5 days, at which point
IL-3 was readded to the media in the presence
of vehicle or the indicated doses of SB-204990
(inh) and incubated for 72 hr further. Cells were
stained with Hoechst 33342 and PI to identify live
G1-gated cells. Histograms shown represent the
forward scatter of live G1-gated cells as an indi-
cator of cell size.ground (Figure 8B) (Hingorani et al., 2005) and manifesting pre-
invasive or invasive pancreatic ductal adenocarcinoma, re-
spectively. Both cell lines have undergone limited passage in
vitro compared to the well-established human tumor lines ana-
lyzed above (Figure 7). These tumors were chosen because the
SB-204990-sensitive A549 cell line also harbors an activating
K-ras mutation (Mitchell et al., 1995), and Ras has previously
been shown to induce tumor cell metabolic conversion to aero-
bic glycolysis (Blum et al., 2005). Treatment with SB-204990
as described above resulted in significant growth inhibition
against xenografts from both cell lines (Figure 8).
Discussion
In this report, we demonstrate that ACL, a key enzyme integrat-
ing glucose and lipid metabolism, contributes to de novo glu-
cose-dependent lipid synthesis by tumor cells. Furthermore,
genetic and pharmacologic downregulation of ACL activity in
cancer cell lines results in a dose-dependent inhibition of cell
proliferation in vitro and tumor growth in vivo. The ability of
ACL inhibition to suppress tumor growth correlates with the
glycolytic phenotype of the tumor. Cancer cells displaying high
rates of glucose metabolism are more severely affected, whereas
those displaying a low rate of aerobic glycolysis are largely un-
affected. The basis for the different sensitivity profiles of tumor
cells to ACL inhibition is consistent with a model in which cells
with a higher flux of glycolytic carbons from the cytosol to the
mitochondria depend on glucose for lipid synthesis necessary
to support their growth to a greater extent than their less glyco-
lytic counterparts. The fact that ACL levels and activity can
increase through the same signaling pathways that stimulate
glycolytic metabolism and that are often deregulated in glyco-CANCER CELL : OCTOBER 2005lytic tumors (the PI3K/Akt pathway) (Berwick et al., 2002;
Board and Newsholme, 1996) suggests that this upregulation
of ACL contributes significantly to the growth advantage and
proliferation rate of tumors displaying aerobic glycolysis.
A predicted consequence of ACL downregulation is the im-
pairment of glucose-dependent lipid synthesis, which we have
documented by both genetic and pharmacologic means. How-
ever, the failure of ACL downregulation to inhibit the growth
of tumors that do not display high levels of aerobic glycolysis
suggests that there are alternative salvage lipogenic pathways
that tumor cells can use to produce acetyl-CoA independently
of ACL. Cytosolic acetyl-CoA can also be generated from ace-
tate via cytoplasmic ACAS2 (Sone et al., 2002). ACAS2 activity
is present in the cell lines that we analyzed and leads to the
incorporation of [1-14C]acetate into lipids in a manner that is
not affected by ACL inhibition. In cells displaying low rates of
aerobic glycolysis, this pathway may compensate for the low
rates of glucose-dependent lipid synthesis, as we observed in
cytochrome c null cells. However, acetate is not an abundant
metabolite, and its conversion to acetyl-CoA is an energy-
dependent process, while the production of acetyl-CoA from
glucose is energy producing (see Figure 1).
Our work suggests that the rate of acetyl-CoA generation
by salvage pathways independent of ACL can be sufficient to
maintain macromolecular synthesis in quantities that support
transformation. Thus, ACL inhibitors, like statins, farnesyl trans-
ferase inhibitors, and FAS inhibitors are unlikely to be effective
therapeutics for all cancers. However, our data predict that tu-
mors displaying a high rate of aerobic glycolysis are likely to
be more dependent on ACL for the generation of cytosolic ace-
tyl-CoA. For these tumors, ACL inhibition provides a potential
advantage over strategies targeting other lipogenic enzymes317
A R T I C L EFigure 7. The sensitivity profile of human cancer cell lines to ACL inhibition
by SB-204990 in vitro and in vivo correlates with their dependence on gly-
colytic metabolism
A: The in vitro sensitivity of three human cancer cell lines to SB-204990 was
determined as described in the Experimental Procedures, after a 3 day
treatment. Plotted is the mean ± SD of triplicate samples from a represen-
tative experiment. IC50 values for A549, PC3, and SKOV3 were 24 M, 26
M, and 53 M, respectively.
B and C: Tumor cell lines were plated at equal densities and fed fresh
media plus 1% FCS at time 0. The concentrations of glucose (B) and lactate
(C) in the media were determined over a 3 day period as described in the
Experimental Procedures. Data points represent the mean ± SD of tripli-
cate samples.
D: Tumor cell lines were preincubated in media plus 1% FCS for 24 hr, and
the level of their glucose-dependent lipid synthesis was determined as de-
scribed in the Experimental Procedures. Data points represent the mean ±
SD of triplicate samples.
E: Tumors were established in athymic nude female mice by subcutaneous
injection of the indicated cancer cell lines. Cohorts of mice with compara-
ble rates of tumor growth were divided randomly into untreated and SB-
204990-treated groups (day 0) and treated with vehicle or SB-204990, as
described in the Experimental Procedures. Graphed is the mean tumor
mass ± SEM from an experiment that is representative of three indepen-
dent experiments.because ACL is located upstream of the other lipogenic en-
zymes. Thus, ACL inhibition can affect the cholesterol, isopren-
oid, and fatty acid synthesis pathways in combination (Figure
1). In addition, ACL inhibition affects mitochondrial homeosta-
sis and membrane potential, presumably through the increased
availability of mitochondrial citrate for full oxidation and NADH
production in the TCA cycle, as previously observed upon ACL
inhibition by hydroxycitrate (Board and Newsholme, 1996).
Owing to its novel mechanism of action, it should be beneficial318to inhibit ACL in combination with other agents used to treat
patients with advanced malignancies, such as agents that
block oncogenic receptor signaling (Tibes et al., 2005). Since
many of these oncogenic signaling cascades activate the PI3K/
Akt pathway, which regulates both glucose and lipid metabo-
lism (Elstrom et al., 2004) as well as ACL levels and activity
(Berwick et al., 2002), ACL inhibition in combination with tyro-
sine kinase or PI3K/Akt inhibitors may act to further abrogate
the metabolic effects downstream of PI3K/Akt activation.
Another striking phenotype that we observed upon both ge-
netic and pharmacologic ACL inhibition, namely the inhibition
of tumor growth and induction of differentiation, has previously
been observed by other manipulations that suppress glycolysis
in tumor cells, such as inhibition of the insulin-like growth fac-
tor I receptor (IGF-IR) by stable expression of a dominant-
negative IGF-IR in A549 cells (Jiang et al., 1999) or inhibition
of BCR-ABL signaling by treatment with Gleevec in K562 cells
(Boren et al., 2001). Furthermore, previous work has shown the
induction of differentiation in the HT29 colon adenocarcinoma
tumor cell line model, upon incubation of cells with butyrate,
which can act as an alternative substrate for mitochondrial oxi-
dation and lipogenesis, in place of glucose (Boren et al., 2003).
A decrease in aerobic glycolysis and glucose-dependent lipid
synthesis was observed in butyrate-treated cells. Together, these
results suggest that aerobic glycolysis may contribute to the
suppression of tumor cell differentiation by stimulating cyto-
solic acetyl-CoA production and lipid synthesis through ACL.
Upon interruption of its high glucose-to-lipid flux, factors in the
in vivo tumor microenvironment may allow a tumor cell to initi-
ate adaptive responses, such as differentiation, in order to
maintain its survival. It is tempting to speculate that certain
glycolytically derived metabolic intermediates may serve as
signals orchestrating these events. One of these intermediates
is glycolytically derived citrate. Disrupting citrate transport to
the cytosol may be another potential strategy for targeting gly-
colytically converted tumors.
In conclusion, the conversion of tumors to a highly glucose-
dependent metabolism, as measured by FDG-PET imaging,
identifies a group of advanced malignancies, for which few
therapeutic options currently exist. Here, we demonstrate that
this conversion to a glucose-dependent metabolism (aerobic
glycolysis) significantly enhances the rate at which tumors
grow and that at least part of this increased growth comes from
increased, glucose-dependent production of cytosolic acetyl-
CoA by ACL. ACL inhibition, either by being cytostatic for cells
exhibiting glucose-dependent growth or by inducing differenti-
ation, provides a novel mechanism to suppress cancer pro-
gression. As an antineoplastic strategy, ACL inhibition would
be relatively tumor-selective and spare normal tissues, since
vegetative and nonglycolytic cells are significantly less depen-
dent on ACL activity.
Experimental procedures
Cell culture
Cell culture reagents were purchased from Invitrogen (Carlsbad, CA), unless
otherwise indicated. IL-3-dependent cell lines were grown in the presence
or absence of IL-3 as previously described (Plas et al., 2001; Lum et al.,
2005). The human cancer cell lines A549, PC3, SKOV3, and K562 were
obtained from the ATCC (Manassas, VA) and grown in medium supple-
mented with 10% heat-inactivated fetal calf serum (Gemini), 10 mM HEPES,
100 U/ml penicillin, 100 g/ml streptomycin. The cytochrome c null andCANCER CELL : OCTOBER 2005
A R T I C L EFigure 8. Inhibition of tumor growth by intraperi-
toneal administration of SB-204990 in nude mice
carrying xenografts of mouse pancreatic ductal
cell lines bearing oncogenic K-rasG12D alleles
Tumors were established in athymic nude fe-
male mice by subcutaneous injection of the
indicated cell lines. Cohorts of mice with com-
parable rates of tumor growth were divided
randomly into untreated and SB-204990-treated
groups (day 0) and treated by i.p. injection of
SB-204990 at a dose of 350 mol/kg/day (135
mg/kg/day) once daily for 12 days. Graphed is
the mean tumor mass ± SEM.wild-type mouse embryonic cell lines were cultured as previously described
(Mansfield et al., 2005).
Flow cytometry
For cell cycle analysis, triplicate samples of cells were pulsed for 90 min
with 10 M BrdU (Sigma) and were then fixed, stained with an anti-BrdU
mAb (PharMingen) and propidium iodide (PI), and analyzed by flow cyto-
metry using an LSR flow cytometer (BD Biosciences). Cell viability was de-
termined by the exclusion of 10 g/ml DAPI (Molecular Probes) as deter-
mined by flow cytometry. To examine MMP, cells were stained in triplicate
with 20 nM tetramethyl rhodamine ethyl ester (TMRE; Molecular Probes)
and 10 g/ml DAPI (Molecular Probes) for 30 min at 37°C in the presence
or absence of the mitochondrial uncoupler FCCP (50 M; Sigma).
Western blotting
Equivalent amounts of total cell protein were loaded onto 4%–12% Bis-Tris
gels (Invitrogen), as previously described (Lum et al., 2005). Proteins were
transferred to a PVDF membrane, membranes were blocked with BLOTTO
(5% nonfat dry milk and 0.1% Tween 20 in PBS) and incubated with a rabbit
antiserum generated against the ACL peptide IGHYLDQKRLKQGLYRH
(1:1000) or with a mouse anti-actin antibody (1:10,000) (Sigma A5441) at
4°C overnight. Membranes were washed in PBS plus 0.1% Tween 20 and
probed with anti-rabbit or anti-mouse HRP-conjugated secondary antibody
(both at 1:10,000 dilution), and proteins were detected using the ECL Plus
chemiluminescence detection reagent (Amersham Biosciences).
siRNA, shRNA, and transfections
siRNA oligonucleotides targeting ACL and control siRNA-targeting lucifer-
ase were obtained from Invitrogen. The ACL1 siRNA sequence is 5#-GCCA
GAACUUGGUAGUCAATT-3#. The ACL4 siRNA sequence is 5#-GGCAUGUC
CAACGAGCUCAATT-3#. The luciferase siRNA sequence is 5#-CGUACGC
GGAAUACUUCGATT-3#. Transfections were performed using Lipofectamine
2000 (Invitrogen) according to the manufacturer’s instructions. Briefly, 4 l of
a 20 M siRNA solution and 2 l of Lipofectamine 2000 were incubated in
200 l of serum-free Optimem media (Invitrogen) for 20 min and overlaid onto
cells cultured in 1 ml of DMEM, 10% FCS without pen/strep in a 12-well plate.
The pKD shRNA constructs used to express short hairpins for RNAi were
derived as previously described (Edinger et al., 2003). The ACL4 shRNA
sequence (sense) is 5#-GGCATGTCCAACGAGCTCAA-3#. The ACL1 shRNA
is 5#-GCCTCTTCAATTTCTACGAGGACTT-3#. Stable clones were selected
by puromycin resistance followed by limiting dilution.
Lipid synthesis
Samples were assayed for lipid synthesis through D-[6-14C]glucose or
[1-14C]acetate in triplicate. To begin the assay, 4 Ci/ml D-[6-14C]glucose
(72 M final concentration) or 2 Ci/ml [1-14C]acetate (36 M final concen-
tration) was added to the cells, and cells were incubated at 37°C for 2 hr.
For experiments measuring inhibition of lipid synthesis by the ACL inhibitor
SB-204990, cells were preincubated with the drug (60 M) for 2 hr prior to
the addition of the radioactive lipid precursors. For adherent cells grown on
a 12-well plate, lipids were extracted by the addition of 500 l of a hexane:CANCER CELL : OCTOBER 2005isopropanol solution (3:2 ratio). Wells were washed with an additional 500
l of hexane:isopropanol solution, and extracts were combined and dried
under N2, resuspended in 50 l of chloroform, and counted in ScintiVerse
(Fisher) on a Beckman LS 6500 scintillation counter. Protein concentration
was determined by a Lowry protein assay. For suspension cells, cellular
lipids were extracted by a modification of the Bligh-Dyer protocol (Bligh and
Dyer, 1959).
ACL activity and acetyl-CoA assays
ACL activity was measured via the malate dehydrogenase-coupled method
(Srere, 1959). The change in absorbance in the absence of exogenous ATP
was subtracted from that in the presence of ATP, and the difference was
normalized to the total protein concentration in order to determine the spe-
cific ACL activity. Acetyl-CoA was measured by an enzymatic amplification
method as previously described (Kato, 1975). Briefly, 3 × 106 cells were
plated on a 10 cm plate and treated overnight with 60 M SB-204990 or
vehicle. The next day, cells were harvested in PBS, 0.5 mM EDTA, and the
pellet was deproteinized in 50 l 6% perchloric acid and neutralized with
27.2 l 2 M KHCO3. Twenty microliters of cleared supernatants were incu-
bated at 30°C × 10 min with 5 l 0.1 mM NEM in 0.5 M Tris (pH 7.4) buffer
for CoASH elimination. Five microliter aliquots were then added to a reac-
tion mixture containing 100 mM Tris (pH 7.4), 10 mM NH4CL, 0.02% w/v
BSA, 1.2 mM oxaloacetate, 1.9 mM acetylphosphate, 36 U phosphotrans-
acetylase, 6 U citrate synthase, and 4 M glutathione and incubated ×1 hr
at 30°C. Samples were boiled ×5 min, and 50 l of supernatants were used
for the indicator reaction as previously described (Dagley, 1965).
Glucose and lactate measurements
Tumor cell lines were plated at a concentration of 100,000 cells/ml in RPMI
10% FCS. The following day, medium was replaced with RPMI 1% FCS,
and cells were incubated for 3 additional days. Medium samples were col-
lected each day and stored at −20°C until the time of the assay. Glucose
and lactate were measured using colorimetric kits according to the manu-
facturer’s instructions (CMA/Microdialysis).
Erythroid differentiation analysis
Induction of surface expression of the erythroid marker glycophorin A was
determined by indirect immunofluorescence and flow cytometry. Cells were
stained with a mouse FITC-conjugated anti-glycophorin A antibody (Dako)
at 1:100 dilution in medium plus 10% FCS for 30 min at 4°C. As a control,
cells were stained with FITC-conjugated IgG. Cells expressing hemoglobin
were determined by benzidine staining as previously described (Park et al.,
2001). The proportion of blue-stained cells was quantified under light mi-
croscopy. A total of 500 cells were counted for each sample in triplicate.
Shown is the mean ± SD of a representative experiment.
In vitro drug inhibition assay
Cells were plated in 96-well plates at a density of 3000 cells per well and
incubated with RPMI medium supplemented with 1% FCS and the indi-
cated concentrations of vehicle or the ACL inhibitor SB-204990. The drug
solution was prepared by mixing equimolar amounts of SB-204990 and319
A R T I C L Esodium bicarbonate in water to achieve a pH of 7.4. At the indicated times,
a sulforhodamine B assay was performed using a kit (Sigma, cat. no. TOX6),
according to the manufacturer’s instructions.
In vivo antitumor activity of ACL inhibition
Early passage, exponentially growing tumor cell lines in culture were har-
vested and washed twice with PBS before being resuspended in PBS at a
concentration of 50 × 106 cells/ml. Tumors were established in athymic
nude female mice (8–10 weeks old; Charles River) by subcutaneous injec-
tion of 10 × 106 cells in a 200 l volume. Unless otherwise indicated, the
tumor size was measured weekly, and tumors were excised for weight mea-
surements, histological examination, and mucicarmine staining 60 days af-
ter cell injection. For the drug treatment groups, cohorts of mice with com-
parable size tumors were divided randomly 3–5 weeks following tumor cell
injection into two groups: untreated (injected with vehicle alone) and treated
(injected with SB-204990) animals. The animals were monitored daily until
treatment was complete. Body weight and tumor size were measured every
2–3 days. Tumor growth was recorded by the measurement (with calipers)
of two perpendicular diameters of the tumor. Tumor mass (in mg) was calcu-
lated by the formula 1/2(a × b2), where a is the long diameter (in mm) and
b is the short diameter (in mm) (Wang et al., 1999). SB-204990 was admin-
istrated to treated animals via i.p. injection at a dose of 350 mol/kg/day
(135 mg/kg/day) once daily for 14 days. This dose has previously been
shown to produce hypolipidemic effects in rodents (Pearce et al., 1998). All
procedures were approved by the Institutional Animal Care and Use Com-
mittee of the University of Pennsylvania.
Tumor histology and immunohistochemistry
Tumors were excised, formalin fixed for 24 hr, and embedded in paraffin.
Sections were cut at 5 m and stained with Gill’s hematoxylin solution #3 and
eosin (both from Fisher Scientific) for H&E or with the mucicarmine staining kit
(Sigma) for mucin production. Immunohistochemistry for caspase activation
was performed using an active caspase-3 rabbit antibody (R&D Systems
AF835) at a 1:1000 antibody dilution on an Autostainer Plus automated staining
system (DAKOCytomation), according to the manufacturer’s instructions.
Slides were counterstained with Gill’s hematoxylin solution #3.
Statistical analysis
The masses of tumors, generated in nude mice by injection of either vector
or ACL knockdown cells in either flank of each mouse, were compared
using the Wilcoxon matched-pairs signed-ranks test for matched pairs of
nonparametric observations. Glucose- and acetate-dependent lipid synthe-
sis across siLUC versus siACL-treated cells was compared by the Mann-
Whitney test for two unmatched samples. All p values are two sided. Statis-
tical analysis was carried out using the STATA program (STATA v.8, STATA
Corporation College Station, TX, 2003).
Supplemental data
The Supplemental Data include two supplemental figures and can be found
with this article online at http://www.cancercell.org/cgi/content/full/8/4/311/
DC1/.
Acknowledgments
The authors thank Debra Cromley and Daniel Martinez for excellent techni-
cal assistance and Jeffrey Billheimer, Jane Glick, and members of the
Thompson laboratory for helpful discussions and comments on the manu-
script. G.H. is a Damon Runyon Fellow supported by the Damon Runyon
Cancer Research Foundation (DRG-#1714-02). This work was supported
by grants from the NIH and GlaxoSmith-Kline.
Received: April 11, 2005
Revised: September 9, 2005
Accepted: September 28, 2005
Published: October 17, 2005
References
Baggetto, L.G. (1992). Deviant energetic metabolism of glycolytic cancer
cells. Biochimie 74, 959–974.320Bauer, D.E., Harris, M.H., Plas, D.R., Lum, J.J., Hammerman, P.S., Rathmell,
J.C., Riley, J.L., and Thompson, C.B. (2004). Cytokine stimulation of aerobic
glycolysis in hematopoietic cells exceeds proliferative demand. FASEB J.
18, 1303–1305.
Berwick, D.C., Hers, I., Heesom, K.J., Moule, S.K., and Tavare, J.M. (2002).
The identification of ATP-citrate lyase as a protein kinase B (Akt) substrate
in primary adipocytes. J. Biol. Chem. 277, 33895–33900.
Bligh, E.G., and Dyer, W.J. (1959). A rapid method of total lipid extraction
and purification. Can. J. Biochem. Physiol. 37, 911–917.
Blum, R., Jacob-Hirsch, J., Amariglio, N., Rechavi, G., and Kloog, Y. (2005).
Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1α,
causing glycolysis shutdown and cell death. Cancer Res. 65, 999–1006.
Board, M., and Newsholme, E. (1996). Hydroxycitrate causes altered pyr-
uvate metabolism by tumorigenic cells. Biochem. Mol. Biol. Int. 40, 1047–
1056.
Boren, J., Cascante, M., Marin, S., Comin-Anduix, B., Centelles, J.J., Lim,
S., Bassilian, S., Ahmed, S., Lee, W.N., and Boros, L.G. (2001). Gleevec
(STI571) influences metabolic enzyme activities and glucose carbon flow
toward nucleic acid and fatty acid synthesis in myeloid tumor cells. J. Biol.
Chem. 276, 37747–37753.
Boren, J., Lee, W.N., Bassilian, S., Centelles, J.J., Lim, S., Ahmed, S.,
Boros, L.G., and Cascante, M. (2003). The stable isotope-based dynamic
metabolic profile of butyrate-induced HT29 cell differentiation. J. Biol.
Chem. 278, 28395–28402.
Buzzai, M., Bauer, D.E., Jones, R.G., Deberardinis, R.J., Hatzivassiliou, G.,
Elstrom, R.L., and Thompson, C.B. (2005). The glucose dependence of Akt-
transformed cells can be reversed by pharmacologic activation of fatty acid
β-oxidation. Oncogene 24, 4165–4173.
Crabtree, H.G. (1929). Observations on the carbohydrate metabolism of tu-
mours. Biochem. J. 23, 536–545.
Dagley, S. (1965). Citrate, UV spectrophotometric determination. In Meth-
ods of Enzymatic Analysis, H.W. Bergmeyer, ed. (New York: Academic
Press), pp. 1562–1565.
Dang, C.V., and Semenza, G.L. (1999). Oncogenic alterations of metabo-
lism. Trends Biochem. Sci. 24, 68–72.
Detterbeck, F.C., Vansteenkiste, J.F., Morris, D.E., Dooms, C.A., Khandani,
A.H., and Socinski, M.A. (2004). Seeking a home for a PET, part 3: Emerging
applications of positron emission tomography imaging in the management
of patients with lung cancer. Chest 126, 1656–1666.
Druker, B.J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G.M., Fanning,
S., Zimmermann, J., and Lydon, N.B. (1996). Effects of a selective inhibitor
of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med.
2, 561–566.
Edinger, A.L., Cinalli, R.M., and Thompson, C.B. (2003). Rab7 prevents
growth factor-independent survival by inhibiting cell-autonomous nutrient
transporter expression. Dev. Cell 5, 571–582.
Elstrom, R.L., Bauer, D.E., Buzzai, M., Karnauskas, R., Harris, M.H., Plas,
D.R., Zhuang, H., Cinalli, R.M., Alavi, A., Rudin, C.M., and Thompson, C.B.
(2004). Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 64,
3892–3899.
Gambhir, S.S. (2002). Molecular imaging of cancer with positron emission
tomography. Nat. Rev. Cancer 2, 683–693.
Hingorani, S.R., Petricoin, E.F., Maitra, A., Rajapakse, V., King, C., Jacobetz,
M.A., Ross, S., Conrads, T.P., Veenstra, T.D., Hitt, B.A., et al. (2003). Prein-
vasive and invasive ductal pancreatic cancer and its early detection in the
mouse. Cancer Cell 4, 437–450.
Hingorani, S.R., Wang, L., Multani, A.S., Combs, C., Deramaudt, T.B., Hru-
ban, R.H., Rustgi, A.K., Chang, S., and Tuveson, D.A. (2005). Trp53R172H
and KrasG12D cooperate to promote chromosomal instability and widely
metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7,
469–483.
Jackowski, S., Wang, J., and Baburina, I. (2000). Activity of the phos-
phatidylcholine biosynthetic pathway modulates the distribution of fattyCANCER CELL : OCTOBER 2005
A R T I C L Eacids into glycerolipids in proliferating cells. Biochim. Biophys. Acta 1483,
301–315.
Jiang, Y., Rom, W.N., Yie, T.A., Chi, C.X., and Tchou-Wong, K.M. (1999).
Induction of tumor suppression and glandular differentiation of A549 lung
carcinoma cells by dominant-negative IGF-I receptor. Oncogene 18,
6071–6077.
Kaplan, R.S., Mayor, J.A., and Wood, D.O. (1993). The mitochondrial tri-
carboxylate transport protein. cDNA cloning, primary structure, and com-
parison with other mitochondrial transport proteins. J. Biol. Chem. 268,
13682–13690.
Kato, T. (1975). CoA cycling: an enzymatic amplification method for deter-
mination of CoASH and acetyl CoA. Anal. Biochem. 66, 372–392.
Katz, N.R., and Giffhorn, S. (1983). Glucose- and insulin-dependent induc-
tion of ATP citrate lyase in primary cultures of rat hepatocytes. Biochem. J.
212, 65–71.
Kohmura, K., Miyakawa, Y., Kawai, Y., Ikeda, Y., and Kizaki, M. (2004). Dif-
ferent roles of p38 MAPK and ERK in STI571-induced multi-lineage differen-
tiation of K562 cells. J. Cell. Physiol. 198, 370–376.
Kuhajda, F.P. (2000). Fatty-acid synthase and human cancer: new perspec-
tives on its role in tumor biology. Nutrition 16, 202–208.
Lum, J.J., Bauer, D.E., Kong, M., Harris, M.H., Li, C., Lindsten, T., and
Thompson, C.B. (2005). Growth factor regulation of autophagy and cell sur-
vival in the absence of apoptosis. Cell 120, 237–248.
Mansfield, K.D., Guzy, R.D., Pan, Y., Young, R.M., Cash, T.P., Schumacker,
P.T., and Simon, M.C. (2005). Mitochondrial dysfunction resulting from loss
of cytochrome c impairs cellular oxygen sensing and hypoxic HIF-α activa-
tion. Cell Metab. 1, 393–399.
Medes, G., Thomas, A., and Weinhouse, S. (1953). Metabolism of neoplas-
tic tissue. IV. A study of lipid synthesis in neoplastic tissue slices in vitro.
Cancer Res. 13, 27–29.
Mitchell, C.E., Belinsky, S.A., and Lechner, J.F. (1995). Detection and quanti-
tation of mutant K-ras codon 12 restriction fragments by capillary electro-
phoresis. Anal. Biochem. 224, 148–153.
Nakashima, R.A., Paggi, M.G., and Pedersen, P.L. (1984). Contributions of
glycolysis and oxidative phosphorylation to adenosine 5#-triphosphate pro-
duction in AS-30D hepatoma cells. Cancer Res. 44, 5702–5706.
Ookhtens, M., Kannan, R., Lyon, I., and Baker, N. (1984). Liver and adipose
tissue contributions to newly formed fatty acids in an ascites tumor. Am. J.
Physiol. 247, R146–R153.
Park, J.I., Choi, H.S., Jeong, J.S., Han, J.Y., and Kim, I.H. (2001). Involve-
ment of p38 kinase in hydroxyurea-induced differentiation of K562 cells.
Cell Growth Differ. 12, 481–486.
Pearce, N.J., Yates, J.W., Berkhout, T.A., Jackson, B., Tew, D., Boyd, H.,
Camilleri, P., Sweeney, P., Gribble, A.D., Shaw, A., and Groot, P.H. (1998).
The role of ATP citrate-lyase in the metabolic regulation of plasma lipids.CANCER CELL : OCTOBER 2005Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP
citrate-lyase inhibitor SB-201076. Biochem. J. 334, 113–119.
Plas, D.R., Talapatra, S., Edinger, A.L., Rathmell, J.C., and Thompson, C.B.
(2001). Akt and Bcl-xL promote growth factor-independent survival through
distinct effects on mitochondrial physiology. J. Biol. Chem. 276, 12041–
12048.
Sabine, J.R., Abraham, S., and Chaikoff, I.L. (1967). Control of lipid metabo-
lism in hepatomas: insensitivity of rate of fatty acid and cholesterol synthe-
sis by mouse hepatoma BW7756 to fasting and to feedback control. Cancer
Res. 27, 793–799.
Shara, M., Ohia, S.E., Yasmin, T., Zardetto-Smith, A., Kincaid, A., Bagchi,
M., Chatterjee, A., Bagchi, D., and Stohs, S.J. (2003). Dose- and time-
dependent effects of a novel (−)-hydroxycitric acid extract on body weight,
hepatic and testicular lipid peroxidation, DNA fragmentation and histopath-
ological data over a period of 90 days. Mol. Cell. Biochem. 254, 339–346.
Shiotsu, Y., Neckers, L.M., Wortman, I., An, W.G., Schulte, T.W., Soga, S.,
Murakata, C., Tamaoki, T., and Akinaga, S. (2000). Novel oxime derivatives
of radicicol induce erythroid differentiation associated with preferential G(1)
phase accumulation against chronic myelogenous leukemia cells through
destabilization of Bcr-Abl with Hsp90 complex. Blood 96, 2284–2291.
Sone, H., Shimano, H., Sakakura, Y., Inoue, N., Amemiya-Kudo, M., Yahagi,
N., Osawa, M., Suzuki, H., Yokoo, T., Takahashi, A., et al. (2002). Acetyl-
coenzyme A synthetase is a lipogenic enzyme controlled by SREBP-1 and
energy status. Am. J. Physiol. Endocrinol. Metab. 282, E222–E230.
Srere, P. (1959). The citrate cleavage enzyme. I. Distribution and purification.
J. Biol. Chem. 234, 2544–2547.
Szutowicz, A., Kwiatkowski, J., and Angielski, S. (1979). Lipogenetic and
glycolytic enzyme activities in carcinoma and nonmalignant diseases of the
human breast. Br. J. Cancer 39, 681–687.
Tibes, R., Trent, J., and Kurzrock, R. (2005). Tyrosine kinase inhibitors and
the dawn of molecular cancer therapeutics. Annu. Rev. Pharmacol. Toxicol.
45, 357–384.
Towle, H.C., Kaytor, E.N., and Shih, H.M. (1997). Regulation of the expres-
sion of lipogenic enzyme genes by carbohydrate. Annu. Rev. Nutr. 17,
405–433.
Turyn, J., Schlichtholz, B., Dettlaff-Pokora, A., Presler, M., Goyke, E., Ma-
tuszewski, M., Kmiec, Z., Krajka, K., and Swierczynski, J. (2003). Increased
activity of glycerol 3-phosphate dehydrogenase and other lipogenic en-
zymes in human bladder cancer. Horm. Metab. Res. 35, 565–569.
Wang, H., Cai, Q., Zeng, X., Yu, D., Agrawal, S., and Zhang, R. (1999).
Antitumor activity and pharmacokinetics of a mixed-backbone antisense
oligonucleotide targeted to the RIα subunit of protein kinase A after oral
administration. Proc. Natl. Acad. Sci. USA 96, 13989–13994.
Warburg, O. (1956). On the origin of cancer cells. Science 123, 309–314.
Zambell, K.L., Fitch, M.D., and Fleming, S.E. (2003). Acetate and butyrate
are the major substrates for de novo lipogenesis in rat colonic epithelial
cells. J. Nutr. 133, 3509–3515.321
